What were the main drivers of Abbott's revenue growth in 2021?

The primary driver of Abbott's revenue growth in 2021 was the strong performance of its Diagnostics segment, particularly the demand for its COVID-19 testing solutions, such as the BinaxNOW and Panbio rapid antigen tests. The Medical Devices segment also contributed significantly with a rebound in sales driven by increased procedure volumes and strong performance in key areas like Diabetes Care and Structural Heart.

How is Abbott managing supply chain disruptions and inflationary pressures?

Abbott is actively managing supply chain challenges and inflationary pressures by implementing price increases in certain businesses and focusing on gross margin improvement initiatives. While the company experienced some availability issues with materials and components, it has managed these challenges without significant supply disruptions to date. Abbott expects these inflationary pressures to continue but aims to mitigate their impact through these strategic actions.

What is Abbott's strategy for future growth?

Abbott's strategy for future growth involves continued investment in its key segments: Diagnostics (focusing on the Alinity suite), Medical Devices (expanding market position across various businesses), Nutritionals (driving global growth and introducing line extensions), and Established Pharmaceuticals (growing its portfolio in emerging markets). The company also maintains a strong commitment to research and development to drive innovation and maintain a competitive edge.

How did the COVID-19 pandemic impact Abbott's different business segments?

The COVID-19 pandemic had varied impacts. The Diagnostics segment saw significant sales increases due to COVID-19 testing. Medical Devices experienced initial declines in procedure-dependent businesses due to the pandemic but saw a strong recovery in 2021. The Established Pharmaceutical Products segment was also affected in emerging markets but recovered in 2021. The Nutritional and Diabetes Care businesses were the least impacted.

ABT 10-K FY2021 Annual Report — Revenue, Net Income, EPS

Summary

Abbott Laboratories' 2021 10-K filing reveals a robust performance, largely driven by significant growth in its Diagnostics segment, primarily fueled by COVID-19 testing solutions. Despite global supply chain challenges and inflationary pressures, the company demonstrated strong overall sales growth. The Medical Devices segment also showed a healthy rebound with double-digit growth in key divisions. The Established Pharmaceuticals and Nutritional Products segments contributed steady growth, though the latter faced some headwinds in international pediatric nutrition. Abbott continues to invest in research and development across its segments, aiming for sustainable growth and market leadership.

Financial Highlights

53 data points

Beta

Revenue

$43.08B

0.6% Gross Margin

Net Income

$7.07B

0.2% Net Margin

EPS (Diluted)

$3.94

Total Assets

$75.20B

Cash & Equivalents

$9.80B

Free Cash Flow

$8.65B

Financial Statements

Beta

Revenue	$43.08B
Cost of Revenue	$18.54B
Gross Profit	$24.54B
R&D Expenses	$2.74B
SG&A Expenses	$11.32B
Operating Expenses	$34.65B
Operating Income	$8.43B
Interest Expense	$533.00M
Net Income	$7.07B
EPS (Basic)	$3.97
EPS (Diluted)	$3.94
Shares Outstanding (Basic)	1.77B
Shares Outstanding (Diluted)	1.79B

Key Highlights

1Abbott Laboratories reported substantial revenue growth in 2021, largely propelled by a significant surge in its Diagnostics segment, driven by COVID-19 testing products like BinaxNOW and Panbio.
2The Medical Devices segment experienced strong recovery, with double-digit growth in Diabetes Care, Structural Heart, and Electrophysiology, signaling a rebound in elective procedures.
3The company maintained a strong financial position, with substantial cash and cash equivalents, and continued its commitment to returning value to shareholders through a significant increase in dividends declared and share repurchases.
4Abbott is actively managing global supply chain challenges and inflationary pressures, implementing strategies to mitigate the impact of rising costs through price increases and efficiency initiatives.
5Research and development remains a key focus, with ongoing investment in innovation across all segments, including new product introductions and enhancements for its FreeStyle Libre diabetes monitoring system and structural heart devices.
6The company's global presence is a significant strength, with international sales comprising approximately 61% of total net sales, demonstrating resilience and diversification.
7Abbott declared a 19% increase in dividends per share in 2021 compared to 2020, reflecting confidence in its financial performance and commitment to shareholder returns.

ABBOTT LABORATORIES Annual Report, Year Ended Dec 31, 2021

Summary

Financial Highlights

Key Highlights

Frequently Asked Questions